Effect of methylprednisolone on bone mineral density in rats with ovariectomy-induced bone loss and suppressed endogenous adrenaline levels by metyrosine.
OBJECTIVES
In this study, effect of methylprednisolone on bone mineral density (BMD) was investigated in rats with overiectomy induced bone lose and suppressed endogenous adrenalin levels, and compared to alendronate.


MATERIALS AND METHODS
Severity of bone loss in the examined material (femur bones) was evaluated by BMD measurement.


RESULTS
The group with the highest BMD value was metyrosinemetyrosine + methylprednisolone combination (0.151 g/cm(2)), while that with the lowest BMD was methylprednisolone (0.123 g/cm(2)). Alendronate was effective only when used alone in ovariectomized rats (0.144 g/cm(2)), but not when used in combination with methylprednisolone (0.124 g/cm(2)). In the ovariectomized rat group which received only metyrosine, BMD value was statistically indifferent from ovariectomized control group.


CONCLUSIONS
Methylprednisolone protected bone loss in rats with suppressed adrenaline levels because of metyrosinemetyrosine.
['Yilmaz|Mehmet|M|', 'Isaoglu|Unal|U|', 'Uslu|Turan|T|', 'Yildirim|Kadir|K|', 'Seven|Bedri|B|', 'Akcay|Fatih|F|', 'Hacimuftuoglu|Ahmet|A|']
D019386:Alendronate D000818:Animals D015519:Bone Density D050071:Bone Density Conservation Agents D004359:Drug Therapy, Combination D004837:Epinephrine D005260:Female D005269:Femur D005938:Glucocorticoids D008775:Methylprednisolone D010024:Osteoporosis D010052:Ovariectomy D051381:Rats D017208:Rats, Wistar D019805:alpha-Methyltyrosine
methylprednisolone Bone mineral density bone loss metirosine osteoporosis ovariectomy